» Articles » PMID: 29187870

Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential

Overview
Journal J Cancer
Specialty Oncology
Date 2017 Dec 1
PMID 29187870
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Philadelphia chromosome-positive (Ph+) leukemia is characterized by reciprocal translocation between chromosomes 9 and 22. The resultant BCR/ABL fusion protein displays constitutive tyrosine kinase activity, leading to the induction of aberrant proliferation and neoplastic transformation. The bone marrow (BM) microenvironment is tumor-promoting, and contributes to disease recurrence in Ph+ leukemia. Activity in the BM microenvironment is mediated by several cellular compartments, extracellular matrix, various soluble factors including transforming growth factor beta 1 (TGF-β1), and the hypoxic conditions in the BM niche. TGF-β1 is released during bone remodeling and plays a role in maintaining leukemic stem cells, as well as being implicated in the epithelial-mesenchymal transition (EMT) process in most solid tumors. Although EMT is largely implicated in epithelial tumors, recent findings argue for an EMT-like process in leukemia as well. The surface receptor CD44 is involved in cell adhesion, cell migration, and homing of normal and malignant hematopoietic stem cells. Elevation of CD44 expression is considered a marker for a worse prognosis in most hematological malignancies. We explored the functions of Snail and Twist1 in Ph+ leukemia. We showed that ectopic expression of Snail and, to a lesser extent, Twist1, upregulates CD44 expression that is β-catenin-dependent. Moreover, the presence of Snail or Twist1 partially blocked phorbol 12-myristate 13-acetate-induced megakaryocyte differentiation, while that of Twist significantly altered imatinib-induced erythroid differentiation. Thus EMT modulators affected proliferation, CD44 gene expression and differentiation ability of Ph+ leukemia cells.

Citing Articles

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.

Fernandez-Tabanera E, Melero-Fernandez de Mera R, Alonso J Front Oncol. 2022; 12:909450.

PMID: 35785191 PMC: 9247467. DOI: 10.3389/fonc.2022.909450.


The functional multipotency of transforming growth factor β signaling at the intersection of senescence and cancer.

Mikula-Pietrasik J, Rutecki S, Ksiazek K Cell Mol Life Sci. 2022; 79(4):196.

PMID: 35305149 PMC: 11073081. DOI: 10.1007/s00018-022-04236-y.


2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.

Khamaisi H, Mahmoud H, Mahajna J Molecules. 2022; 27(3).

PMID: 35164068 PMC: 8839885. DOI: 10.3390/molecules27030804.


Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance.

Dudas J, Ladanyi A, Ingruber J, Steinbichler T, Riechelmann H Cells. 2020; 9(2).

PMID: 32059478 PMC: 7072371. DOI: 10.3390/cells9020428.


Cellular and molecular alterations induced by low‑dose fisetin in human chronic myeloid leukemia cells.

Klimaszewska-Wisniewska A, Grzanka D, Czajkowska P, Halas-Wisniewska M, Durslewicz J, Antosik P Int J Oncol. 2019; 55(6):1261-1274.

PMID: 31638196 PMC: 6831210. DOI: 10.3892/ijo.2019.4889.


References
1.
Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J . Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer. 2016; 16:140. PMC: 4763415. DOI: 10.1186/s12885-016-2182-8. View

2.
Dybko J, Haus O, Jazwiec B, Urbaniak J, Wozniak M, Kaczmar-Dybko A . CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase. Acta Haematol. 2014; 132(2):166-71. DOI: 10.1159/000357373. View

3.
Abba M, Patil N, Leupold J, Allgayer H . MicroRNA Regulation of Epithelial to Mesenchymal Transition. J Clin Med. 2016; 5(1). PMC: 4730133. DOI: 10.3390/jcm5010008. View

4.
Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G . Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002; 30(9):1029-35. DOI: 10.1016/s0301-472x(02)00874-3. View

5.
Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S . Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2010; 117(5):1673-6. DOI: 10.1182/blood-2009-11-254680. View